Comparative associations of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease with risk of incident chronic kidney disease: a cohort study

被引:0
|
作者
Heo, Ji Hye [1 ]
Lee, Mi Yeon [2 ]
Kim, Seong Hwan [3 ]
Zheng, Ming-Hua [4 ,5 ,6 ,7 ]
Byrne, Christopher D. [8 ,9 ]
Targher, Giovanni [1 ,10 ]
Sung, Ki-Chul [1 ,11 ]
机构
[1] Hallym Univ, Coll Med, Dept Internal Med, 1 Hallymdaehak Gil, Chunchon 24252, South Korea
[2] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Div Biostatist,Dept R&D Management, Seoul, South Korea
[3] Korea Univ, Ansan Hosp, Dept Internal Med, Div Cardiol, Ansan, South Korea
[4] Wenzhou Med Univ, Affiliated Hosp 1, MAFLD Res Ctr, Dept Hepatol, Wenzhou, Peoples R China
[5] Wenzhou Key Lab Hepatol, Wenzhou, Peoples R China
[6] Wenzhou Med Univ, Inst Hepatol, Wenzhou, Peoples R China
[7] Key Lab Diag & Treatment Dev Chron Liver Dis Zheji, Wenzhou, Peoples R China
[8] Univ Southampton, Fac Med, Nutr & Metab, Southampton, England
[9] Univ Hosp Southampton, Southampton Natl Inst Hlth & Care Res, Biomed Res Ctr, Southampton, England
[10] IRCCS Sacro Cuore Don Calabria Hosp, Metab Dis Res Unit, Negrar Di Valpolicelle, Italy
[11] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Sch Med, Dept Internal Med, Seoul, South Korea
关键词
Metabolic dysregulation; non-alcoholic fatty liver disease (NAFLD); metabolic syndrome; chronic kidney disease (CKD); albuminuria; DELPHI CONSENSUS STATEMENT;
D O I
10.21037/hbsn-23-558
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: We examined the comparative associations between non-alcoholic fatty liver disease (NAFLD) and metabolic dysfunction-associated steatotic liver disease (MASLD) definitions with risk of developing chronic kidney disease (CKD) and abnormal albuminuria. Methods: We conducted a cohort study of 214,145 Korean adults with normal kidney function at baseline who underwent liver ultrasonography. Participants were further subdivided into no steatotic liver disease (no-SLD), NAFLD-only, MASLD-only, both NAFLD and MASLD, and SLD not categorized as NAFLD or MASLD groups. Cox proportional hazards models were used to analyze the risk of incident CKD and albuminuria. Results: Compared with either the no-NAFLD or no-MASLD groups, the NAFLD and MASLD groups were associated with a higher risk of incident CKD (NAFLD: adjusted hazard ratio (HR), 1.18 [95% CI, 1.01-1.38]; MASLD: adjusted HR, 1.21 [95% CI, 1.04-1.39]). Among the five subgroups, both NAFLD and MASLD group had the strongest association with risk of incident CKD (adjusted HR, 1.21 [95% CI, 1.041.42]). The MASLD-only group had the strongest association with incident abnormal albuminuria, with an adjusted HR comparable to that of the both NAFLD and MASLD group (adjusted HR 1.96 [95% CI, 1.442.67] for the MASLD-only, and adjusted HR 1.98 [95% CI, 1.58-2.49] for the both NAFLD and MASLD group versus the no-SLD group). The NAFLD-only group was not independently associated with risk of CKD or abnormal albuminuria. Conclusions: These findings suggest that MASLD definition identifies individuals at high risk of developing incident CKD or abnormal albuminuria better than NAFLD definition.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Equivalent prevalence and progression of chronic kidney disease in non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease
    Suzuki, Hiroyuki
    Tsutsumi, Tsubasa
    Kawaguchi, Machiko
    Amano, Keisuke
    Kawaguchi, Takumi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [2] Metabolic dysfunction-associated fatty liver disease and risk of incident chronic kidney disease: A nationwide cohort study
    Jung, Chan-Young
    Koh, Hee Byung
    Park, Keun Hyung
    Joo, Young Su
    Kim, Hyung Woo
    Ahn, Sang Hoon
    Park, Jung Tak
    Kim, Seung Up
    DIABETES & METABOLISM, 2022, 48 (04)
  • [3] Dysmetabolic comorbidities and non-alcoholic fatty liver disease: a stairway to metabolic dysfunction-associated steatotic liver disease
    Colaci, Carmen
    Gambardella, Maria Luisa
    Scarlata, Giuseppe Guido Maria
    Boccuto, Luigi
    Colica, Carmela
    Luzza, Francesco
    Scarpellini, Emidio
    Mendez-Sanchez, Nahum
    Abenavoli, Ludovico
    HEPATOMA RESEARCH, 2024, 10
  • [4] Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease
    Hu, Ye
    Sun, Chao
    Chen, Ying
    Liu, Yu-Dong
    Fan, Jian-Gao
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2024, 12 (09) : 802 - 814
  • [5] Clinical profiles and mortality rates are similar for metabolic dysfunction-associated steatotic liver disease and non-alcoholic fatty liver disease
    Younossi, Zobair M.
    Paik, James M.
    Stepanova, Maria
    Ong, Janus
    Alqahtani, Saleh
    Henry, Linda
    JOURNAL OF HEPATOLOGY, 2024, 80 (05) : 694 - 701
  • [6] Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
    Jung, Han Na
    Jung, Chang Hee
    DIABETES & METABOLISM JOURNAL, 2023, 47 (02) : 198 - 200
  • [7] Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics
    Song, Byeong Geun
    Kang, Tae Wook
    Sinn, Dong Hyun
    Kim, Yeun-Yoon
    Min, Ji Hye
    Hwang, Jeong Ah.
    Shin, Jaeseung
    CLINICAL IMAGING, 2024, 108
  • [8] Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: a nationwide cohort study
    Moon, Joon Ho
    Jeong, Seogsong
    Jang, Heejoon
    Koo, Bo Kyung
    Kim, Won
    ECLINICALMEDICINE, 2023, 65
  • [9] Non-alcoholic fatty liver disease increases the risk of incident chronic kidney disease
    Kaps, Leonard
    Labenz, Christian
    Galle, Peter R.
    Weinmann-Menke, Julia
    Kostev, Karel
    Schattenberg, Joern M.
    UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2020, 8 (08) : 942 - 948
  • [10] Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study
    Lee, Hokyou
    Lee, Yong-ho
    Kim, Seung Up
    Kim, Hyeon Chang
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2021, 19 (10) : 2138 - +